TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) in a research report issued on Monday. The brokerage set a “buy” rating on the stock.
A number of other analysts have also recently issued reports on DMRA. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Evercore initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target for the company. Guggenheim reissued a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Wedbush began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, May 28th. They issued an “outperform” rating and a $35.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.
Get Our Latest Research Report on DMRA
Damora Therapeutics, Inc. Common Stock Price Performance
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, equities analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.1 EPS for the current year.
Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock
Large investors have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. Virtu Financial LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Connective Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $100,000. Sigma Planning Corp purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $334,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.
Damora Therapeutics, Inc. Common Stock Company Profile
Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.
Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.
Featured Articles
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong
- Meta Unveils Subscriptions: A New Offering With Real Growth Potential
- 3 Longevity ETFs to Buy and Hold (and Hold)
- The Market May Be Missing What’s Changing at BigBear AI
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
